Veterinary Diagnostics Patents: Who Leads, Where the Gaps Are 2026
- A three-way filing cluster dominates the field. the leading individual assignee sits at 221 records, with three names co-appearing at 216-217 shared filings — evidence of a tightly linked filing group rather than independent competitors.
- Filing has fallen sharply since the 2020 peak. from 25 records in the peak year to 17 in 2021 and down to 4 by 2024, a -76% drop over that span, though 2025-26 figures are still filling in.
- Nucleic-acid and enzyme-testing classes carry the bulk of claim density. C12N and G01N alone cover 55.2% and 40.0% of the 698 records in scope, leaving lab-apparatus (B01L, 3.9%) and peptide/protein (C07K, 6.3%) classes comparatively open.
Filing growth compares 2021 (17 records) with 2024 (4) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
What this landscape covers
This dataset tracks 698 published records filed between 2015 and the 2026 cut-off, spanning veterinary diagnostic assays and therapeutic dosage compositions built around nucleic-acid, enzyme and binding-assay technologies. The search combines diagnostic method terms with formulation and delivery terms, so the corpus sits at the intersection of animal-health testing and the drug or biologic compositions used to treat what those tests find.
Filings route predominantly through the PCT system, with WIPO receiving 275 of the records, followed by national filings in the United States, Europe, Australia, Canada and India. That pattern points to applicants seeking broad multi-jurisdiction cover from a single priority filing rather than staging entry market by market.
Filing trend and technology composition
Two views of the same 698-record corpus: filings by year, and the IPC subclasses those filings sit under.
A peak in 2020, then a steady pull-back
Recorded filings ran from 24 in 2017 to a peak of 25 in 2020, then declined to 17 by 2021 and 4 by 2024 — a -76% fall across that three-year window. Treat 2025 and 2026 as incomplete: publication typically lags filing by around 18 months, so the most recent years will fill in as more records publish.
Claim density sits in nucleic-acid and testing classes
C12N (microorganisms & genetic engineering) and G01N (material analysis & testing) each cover well over a third of the 698 records, with A61K (medicinal preparations) and C12Q (enzyme/DNA measuring) also carrying substantial share. B01L (lab apparatus) and C07K (peptides & proteins) sit far lower, at 3.9% and 6.3% respectively.
Shares are the percentage of the 698 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Veterinary Diagnostics & Therapeutics Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about veterinary diagnostics & therapeutics patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in this corpus
Co-binder assisted assay methods
The present invention is directed to methods for reducing cross-reactivity between species employed in multiplexed immunoassays.Filed by Meso Scale Technologies, LLC (2014-10-23). Illustrative of the binding-assay approach to reducing cross-reactivity in multi-species diagnostic panels — a recurring design problem across the G01N-classed portion of this corpus.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20130011922A1 | Nucleic acid compounds for inhibiting gene expression and uses thereof | 349 |
| 2 | US20070275465A1 | Double-Stranded Ribonucleic Acid with Increased Effectiveness in an Organism | 221 |
| 3 | WO2008049078A1 | Nicked or gapped nucleic acid molecules and uses thereof | 165 |
| 4 | EP2752664A1 | Label-free method for the detection of analytes | 116 |
| 5 | US20060110739A1 | Biosensors for detecting macromolecules and other analytes | 109 |
| 6 | US7786290B2 | Double-stranded ribonucleic acid with increased effectiveness in an organism | 107 |
| 7 | WO2005014782A2 | Double-stranded ribonucleic acid with increased effectiveness in an organism | 98 |
| 8 | US20020037506A1 | Aptamer based two-site binding assay | 95 |
| 9 | US20050019836A1 | Bioanalytical reagent, method for production thereof, sensor platforms and detection methods based on use of … | 81 |
| 10 | US20080044834A1 | Three-component biosensors for detecting macromolecules and other analytes | 77 |
Citation counts favour older filings that have had more time to accumulate citations within this searched corpus — read them as a signal of influence on the field, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Read together, the ranking, trend and citation data point to a field where claim space concentrated early around a small filing group and has since gone quiet at the frontier.
A steep drop-off after the leading names
The leading assignee holds 221 records against 22 for the tenth-ranked name in the 100-company ranking. That gap, combined with three names co-appearing at 216-217 shared filings, suggests a linked filing group rather than a broad competitive field at the top.
Filing volume has fallen from its 2020 peak
Recorded filings peaked at 25 in 2020, then fell to 17 by 2021 and to 4 by 2024 — a -76% decline across that three-year window. 2025-26 counts are still incomplete given typical publication lag, so this should not be read as the field's final trajectory.
Genetic-engineering claims dominate; apparatus claims are thin
C12N (microorganisms & genetic engineering) covers 55.2% of the 698 records, while B01L (lab apparatus) covers only 3.9%. That imbalance suggests apparatus and delivery-hardware claims around these assays remain comparatively open.
Influence sits with early nucleic-acid inhibition filings
The most-cited record in this corpus, on nucleic acid compounds for inhibiting gene expression, carries 349 citations — well ahead of the next-most-cited records. Older nucleic-acid and RNA filings dominate the citation table, consistent with their head start in a searched corpus.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to veterinary diagnostics & therapeutics patent landscape, with the prior art for and against each one.
Who holds the claim space
The assignee ranking is dominated by a small group of individually-named inventors and a handful of corporate filers, with a long tail of single-digit filers behind them.
A single name well ahead of the field
The top-ranked assignee holds 221 records, more than the fifth-placed name's 194 and far ahead of the tenth-placed name's 22. Co-filing patterns show this leader appearing alongside two other individually-named inventors in the strongest co-assignee pairs in the dataset.
Three names consistently co-file
The strongest co-assignee pairs in this corpus all involve the same three individually-named inventors, sharing 216 or 217 records apiece. That pattern points to a single research group or licensing arrangement behind a large share of the top-ranked filings, rather than three independent competitors.
Momentum has stalled across the tracked assignees
Every assignee tracked for recent-year momentum, corporate and individual alike, shows zero filings in the latest year, with one corporate filer down -100% year-on-year. This is consistent with the broader post-2020 decline in the field rather than isolated to any one filer.
| Assignee | Recent year | YoY |
|---|---|---|
| VAISH NARENDRA K | 0 | — |
| QUAY STEVEN C | 0 | — |
| MCSWIGGEN JAMES | 0 | — |
| AHMADIAN MOHAMMAD | 0 | — |
| MDRNA, Inc. | 0 | — |
| Meso Scale Technologies, LLC | 0 | -100% |
| Nastech Pharmaceutical Company | 0 | — |
| Saint Louis University | 0 | — |
Using this landscape in practice
The data points to where claim space is dense and where it has thinned out — the next step is checking a specific filing idea against both.
Check a draft claim against the dense classes
If a proposed filing touches C12N or G01N territory, run it against the existing claim language in that class before drafting further, since these two classes alone cover well over a third of the corpus each.
Search this space in EurekaWatch the linked filing group's next move
The three co-filing individual inventors behind the largest share of top-ranked records have shown zero filings in the latest tracked year; any resumption would be an early signal worth monitoring.
Track assignee activity in EurekaTest white-space claims in thinner classes
B01L and C07K carry the lowest share of the 698 records — worth a freedom-to-operate check before assuming the space is open, since low density is not the same as no prior art.
Run a freedom-to-operate check in EurekaCommon questions on this landscape
The ranking of 100 assignees in this corpus is led by an individually-named inventor with 221 records, well ahead of the fifth-placed name's 194 and the tenth-placed name's 22. Three individually-named inventors also form the strongest co-assignee pairs in the dataset, sharing 216-217 records between each pair, which suggests a tightly linked filing group rather than a broad field of independent corporate competitors. Beyond that group, corporate assignees such as Meso Scale Technologies and Marina Biotech appear further down the ranking with smaller filing counts.
Filing volume peaked at 25 records in 2020 and fell to 17 by 2021 and 4 by 2024, a -76% decline over that three-year span. However, 2025 and 2026 figures are still incomplete because publication typically lags filing by around 18 months, so the most recent years should not be read as the field's final word. The decline through 2024 is real and measurable; whether it continues past that point cannot yet be confirmed from this data.
C12N, covering microorganisms and genetic engineering, appears in 55.2% of the 698 records in scope, and G01N, covering material analysis and testing, appears in 40.0%. A61K (medicinal preparations, 32.1%) and C12Q (enzyme and DNA measuring, 28.5%) also carry substantial share. Because a single record can carry multiple IPC classes, these percentages add up to more than 100%, and they should be read as density indicators rather than a breakdown of the whole field.
The IPC composition data shows B01L (lab apparatus) at only 3.9% of records and C07K (peptides and proteins) at 6.3%, both well below the density seen in C12N and G01N. That gap points to delivery hardware, multiplex cross-reactivity reduction methods, and peptide-carrier formulations as areas with comparatively thinner claim coverage. Thin coverage is not the same as no prior art, so any filing idea in these areas still warrants a dedicated freedom-to-operate check.
WIPO's PCT route receives the largest share of filings in this corpus at 275 records, ahead of the United States at 150, Europe (EPO) at 89, Australia at 45, Canada at 37 and India at 23. The dominance of the PCT route suggests most applicants are seeking broad international priority coverage from a single filing rather than filing nationally market by market. Downstream national-phase entry patterns would need separate data to confirm which of those routes converts into granted local rights.
Research Veterinary Diagnostics & Therapeutics Patent Landscape in depth with Eureka
Go past this page: query the whole veterinary diagnostics & therapeutics patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.